Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer

PURPOSE: We incorporated cetuximab, a chimeric monoclonal antibody against the epidermal growth factor receptor (EGFR), into the induction therapy and subsequent chemoradiotherapy of head and neck cancer (HNC). PATIENTS AND METHODS: Patients with locally advanced HNC, including squamous and undiffer...

詳細記述

保存先:
書誌詳細
主要な著者: Argiris, Athanassios, Heron, Dwight E., Smith, Ryan P., Kim, Seungwon, Gibson, Michael K., Lai, Stephen Y., Branstetter, Barton F., Posluszny, Donna M., Wang, Lin, Seethala, Raja R., Dacic, Sanja, Gooding, William, Grandis, Jennifer R., Johnson, Jonas T., Ferris, Robert L.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2010
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3018361/
https://ncbi.nlm.nih.gov/pubmed/21079141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.30.6423
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料